Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
June 2015, Vol 6, No 5
June 2015, Vol 6, No 5
Increasing Use of Value Analysis Committees in US Hospitals: Implications for Healthcare Providers and Manufacturers
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
June 2015, Vol 6, No 5
Philadelphia, PA—The growing focus on identifying and preventing overpayments and reducing waste in the healthcare system has prompted hospitals to adopt value analysis committees to curb unnecessary medical supply spending. In 2012, as many as 64% of US hospitals were using a value analysis committee to evaluate new devices and new supplies used in their institutions.
Read Article
Adding Ibrutinib to Standard Therapy Reduces Disease Progression by 80% in Previously Treated Patients with CLL
By
Phoebe Starr
Palliative Care
,
Personalized Medicine
June 2015, Vol 6, No 5
Chicago, IL—The combination of ibrutinib (Imbruvica) plus standard therapy with bendamustine (Treanda) and rituximab (Rituxan) significantly reduced the risk for disease progression or death by 80% compared with bendamustine plus rituximab alone in previously treated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), according to lead investigator Asher A. Chanan-Khan, MD, Chair, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL.
Read Article
Early Initiation of Palliative Care Improves Survival in Patients with Advanced Cancer
By
Laura Morgan
Palliative Care
,
Personalized Medicine
June 2015, Vol 6, No 5
Palliative care offers symptom relief, comfort, and peaceful death to patients with advanced cancer. Historically, palliative care was provided to patients who were near death. Based on recent research, however, the American Society of Clinical Oncology now recommends combining palliative care with curative treatment early in the disease course. Nevertheless, an important question remains: How early in the disease trajectory should patients with advanced cancer begin receiving palliative care?
Read Article
Docetaxel Boosts Survival in Patients with Hormone-Naïve Metastatic Prostate Cancer
By
Phoebe Starr
ASCO 2015 Highlights
,
ASCO
June 2015, Vol 6, No 5
Chicago, IL—Adding docetaxel (Taxotere) to standard hormone therapy extends overall survival (OS) by a median of 10 months versus hormone therapy alone in men with newly diagnosed, advanced, hormone therapy–naïve prostate cancer, according to the results of the STAMPEDE trial. The survival benefits were more pronounced in metastatic disease and were less certain in nonmetastatic disease. Another finding of this analysis of STAMPEDE is that zoledronic acid (Zometa) had no benefit in this setting.
Read Article
Immunotherapy Makes Headwinds into Liver Cancer
By
Wayne Kuznar
ASCO 2015 Highlights
,
Immunotherapy
,
ASCO
June 2015, Vol 6, No 5
Chicago, IL—Immunotherapy with nivolumab (Opdivo) resulted in durable responses and promising overall survival (OS) in a dose-escalation and expansion trial of patients with advanced liver cancer. The 12-month OS rate exceeded 60% in patients in whom sorafenib (Nexavar) had failed, and responses occurred in patients with the hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, reported Anthony B. El-Khoueiry, MD, Assistant Professor of Clinical Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, at the 2015 American Society of Clinical Oncology (ASCO) meeting.
Read Article
Oral Nicotinamide Prevents Common Skin Cancers in High-Risk Patients
By
Phoebe Starr
ASCO 2015 Highlights
,
ASCO
June 2015, Vol 6, No 5
Chicago, IL—The prevention of common skin cancers and precancers is possible by taking an inexpensive, widely available, oral pill twice daily. The pill—the vitamin B3 supplement called nicotinamide—cut the rate of new squamous-cell and basal-cell skin cancers by 23% compared with placebo after 1 year among patients at high risk for skin cancer. Nicotinamide also reduced the risk for developing actinic keratosis, a common precancer of the skin.
Read Article
Encouraging Results for Pembrolizumab in Head and Neck Cancer
By
Phoebe Starr
ASCO 2015 Highlights
,
ASCO
June 2015, Vol 6, No 5
Chicago, IL—Pembrolizumab (Keytruda) achieved “remarkable” results in a phase 1 study of previously treated patients with recurrent, squamous-cell carcinoma of the head and neck, according to presenters at the 2015 American Society of Clinical Oncology (ASCO) annual meeting.
Read Article
Adding Radiation to First-Line FOLFOX Reduces Liver Metastases Progression in Patients with Metastatic Colorectal Cancer
By
Walter Alexander
ASCO 2015 Highlights
,
ASCO
June 2015, Vol 6, No 5
Chicago, IL—In patients with metastatic colorectal cancer (mCRC) with liver-dominant metastases who received first-line FOLFOX (leucovorin, fluorouracil [Adrucil], and oxaliplatin [Eloxatin]) with or without bevacizumab (Avastin) plus selective internal radiation therapy (SIRT) compared with FOLFOX with or without bevacizumab, progression-free survival (PFS) in the liver was extended by 7.9 months, according to the results of the SIRFLOX trial, which were presented at the 2015 American Society of Clinical Oncology (ASCO) meeting.
Read Article
“Data in Motion” Will Promote Patient-Centric Care Models
By
Wayne Kuznar
June 2015, Vol 6, No 5
Washington, DC—Personalized medicine will become even more critical as care transitions to patient-centric, outcomes-based care models. The use of real-time data, along with an increasingly advanced understanding of cancer biology, will exponentially increase the number of treatment options for patients, making personalized treatment more effective and ultimately leading to better clinical and financial outcomes.
Read Article
Pathways Reduce Care Variation and Cost of Care, Improve Overall Outcomes
By
Wayne Kuznar
Pathways
June 2015, Vol 6, No 5
Washington, DC—The establishment of pathways in oncology can reduce care variation and enhance value in patient care, said Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna, at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma